NDFIP1 limits cellular TAZ accumulation via exosomal sorting to inhibit NSCLC proliferation
Received date: 23 Aug 2021
Accepted date: 22 Feb 2022
Copyright
NDFIP1 has been previously reported as a tumor suppressor in multiple solid tumors, but the function of NDFIP1 in NSCLC and the underlying mechanism are still unknown. Besides, the WW domain containing proteins can be recognized by NDFIP1, resulted in the loading of the target proteins into exosomes. However, whether WW domain-containing transcription regulator 1 (WWTR1, also known as TAZ) can be packaged into exosomes by NDFIP1 and if so, whether the release of this oncogenic protein via exosomes has an effect on tumor development has not been investigated to any extent. Here, we first found that NDFIP1 was low expressed in NSCLC samples and cell lines, which is associated with shorter OS. Then, we confirmed the interaction between TAZ and NDFIP1, and the existence of TAZ in exosomes, which requires NDFIP1. Critically, knockout of NDFIP1 led to TAZ accumulation with no change in its mRNA level and degradation rate. And the cellular TAZ level could be altered by exosome secretion. Furthermore, NDFIP1 inhibited proliferation in vitro and in vivo, and silencing TAZ eliminated the increase of proliferation caused by NDFIP1 knockout. Moreover, TAZ was negatively correlated with NDFIP1 in subcutaneous xenograft model and clinical samples, and the serum exosomal TAZ level was lower in NSCLC patients. In summary, our data uncover a new tumor suppressor, NDFIP1 in NSCLC, and a new exosome-related regulatory mechanism of TAZ.
Key words: NDFIP1; TAZ; NSCLC; exosome; cargo sorting
Yirui Cheng , Xin Lu , Fan Li , Zhuo Chen , Yanshuang Zhang , Qing Han , Qingyu Zeng , Tingyu Wu , Ziming Li , Shun Lu , Cecilia Williams , Weiliang Xia . NDFIP1 limits cellular TAZ accumulation via exosomal sorting to inhibit NSCLC proliferation[J]. Protein & Cell, 2023 , 14(2) : 123 -136 . DOI: 10.1093/procel/pwac017
1 |
Banik SM, Pedram K, Wisnovsky S et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 2020;584:291–297.
|
2 |
Becker A, Thakur BK, Weiss JM et al. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell 2016;30:836–848.
|
3 |
Ben QW, Sun YW, Liu J et al. Nicotine promotes tumor progression and epithelial-mesenchymal transition by regulating the miR-155-5p/NDFIP1 axis in pancreatic ductal adenocarcinoma. Pancreatology 2020;20:698–708.
|
4 |
Callus BA, Finch-Edmondson ML, Fletcher S et al. YAPping about and not forgetting TAZ. FEBS Lett 2019;593:253–276.
|
5 |
Chairoungdua A, Smith DL, Pochard P et al. Exosome release of beta-catenin: a novel mechanism that antagonizes Wnt signaling. J Cell Biol 2010;190:1079–1091.
|
6 |
Chen YA, Lu CY, Cheng TY et al. WW domain-containing proteins YAP and TAZ in the Hippo pathway as key regulators in stemness maintenance, tissue homeostasis, and tumorigenesis. Front Oncol 2019;9:60.
|
7 |
Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 2005;6:79–86.
|
8 |
Costa-Silva B, Aiello NM, Ocean AJ et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol 2015;17:816–826.
|
9 |
Cui CB, Cooper LF, Yang X et al. Transcriptional coactivation of bone-specific transcription factor Cbfa1 by TAZ. Mol Cell Biol 2003;23:1004–1013.
|
10 |
Fang C, Li J, Qi S et al. An alternatively transcribed TAZ variant negatively regulates JAK-STAT signaling. EMBO Rep 2019;20(6):e47227.
|
11 |
Gorla M, Santiago C, Chaudhari K et al. Ndfip proteins target Robo receptors for degradation and allow commissural axons to cross the mid-line in the developing spinal cord. Cell Rep 2019;26:3298–3312.e4.
|
12 |
Gyorffy B, Surowiak P, Budczies J et al. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer (vol 8, e82241, 2013). PLoS One 2014;9:ARTN e111842.
|
13 |
Han Q, Lv L, Wei J et al. Vps4A mediates the localization and exosome release of beta-catenin to inhibit epithelial-mesenchymal transition in hepatocellular carcinoma. Cancer Lett 2019;457:47–59.
|
14 |
Harding C, Heuser J, Stahl P. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol 1983;97:329–339.
|
15 |
Harvey KF, Shearwin-Whyatt LM, Fotia A et al. N4WBP5, a potential target for ubiquitination by the Nedd4 family of proteins, is a novel golgi-associated protein. J Biol Chem 2002;277:9307–9317.
|
16 |
He S, Li Z, Yu Y et al. Exosomal miR-499a-5p promotes cell proliferation, migration and EMT via mTOR signaling pathway in lung adenocarcinoma. Exp Cell Res 2019;379:203–213.
|
17 |
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018;553:446–454.
|
18 |
Hong JH, Hwang ES, McManus MT et al. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 2005;309:1074–1078.
|
19 |
Howitt J, Low LH, Putz U et al. Ndfip1 represses cell proliferation by controlling Pten localization and signaling specificity. J Mol Cell Biol 2015;7:119–131.
|
20 |
Howitt J, Putz U, Lackovic J et al. Divalent metal transporter 1 (DMT1) regulation by Ndfip1 prevents metal toxicity in human neurons. Proc Natl Acad Sci USA 2009;106:15489–15494.
|
21 |
Jeppesen DK, Fenix AM, Franklin JL et al. Reassessment of exosome composition. Cell 2019;177:428–445.e18.
|
22 |
Lee DH, Goldberg AL. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 1998;8:397–403.
|
23 |
Lewis DR, Check DP, Caporaso NE et al. US lung cancer trends by histologic type. Cancer 2014;120:2883–2892.
|
24 |
Liu Y, Zhang X, Lin JF et al. CCT3 acts upstream of YAP and TFCP2 as a potential target and tumour biomarker in liver cancer. Cell Death Dis 2019;10:ARTN 644.
|
25 |
Lo Sardo F, Strano S, Blandino G. YAP and TAZ in lung cancer: oncogenic role and clinical targeting. Cancers (Basel) 2018;10(5):137.
|
26 |
Lobb RJ, Becker M, Wen SW et al. Optimized exosome isolation protocol for cell culture supernatant and human plasma. J Extracell Vesicles 2015;4:ARTN 27031.
|
27 |
Lu T, Li Z, Yang Y et al. The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer. Cancer Lett 2018;423:36–46.
|
28 |
Ma F, Ding MG, Lei YY et al. SKIL facilitates tumorigenesis and immune escape of NSCLC via upregulating TAZ/autophagy axis. Cell Death Dis 2020;11:ARTN 1028.
|
29 |
Majer O, Liu B, Kreuk LSM et al. UNC93B1 recruits syntenin-1 to dampen TLR7 signalling and prevent autoimmunity. Nature 2019;575:366–370.
|
30 |
Mc Namee N, O’Driscoll L. Extracellular vesicles and anti-cancer drug resistance. Bba-Rev Cancer 2018;1870:123–136.
|
31 |
Menck K, Sonmezer C, Worst TS et al. Neutral sphingomyelinases control extracellular vesicles budding from the plasma membrane. J Extracell Vesicles 2017;6:1378056.
|
32 |
Miao YX, Li GJ, Zhang XL et al. A TRP channel senses lysosome neutralization by pathogens to trigger their expulsion. Cell 2015;161:1306–1319.
|
33 |
Monypenny J, Milewicz H, Flores-Borja F et al. ALIX regulates tumor-mediated immunosuppression by controlling EGFR activity and PD-L1 presentation. Cell Rep 2018;24:630–641.
|
34 |
O’Leary CE, Riling CR, Spruce LA et al. Ndfip-mediated degradation of Jak1 tunes cytokine signalling to limit expansion of CD4+ effector T cells. Nat Commun 2016;7:ARTN 11226.
|
35 |
Oliver PM, Cao X, Worthen GS et al. Ndfip1 protein promotes the function of itch ubiquitin ligase to prevent T cell activation and T helper 2 cell-mediated inflammation. Immunity 2006;25:929–940.
|
36 |
Ostrowski M, Carmo NB, Krumeich S et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol 2010;12:19–30; sup pp 11-13.
|
37 |
Peng J, Liu HL, Liu CH. MiR-155 promotes uveal melanoma cell proliferation and invasion by regulating NDFIP1 expression. Technol Cancer Res Treat 2017;16:1160–1167.
|
38 |
Pocaterra A, Romani P, Dupont S. YAP/TAZ functions and their regulation at a glance. J Cell Sci 2020;133:ARTN jcs230425.
|
39 |
Putz U, Howitt J, Doan A et al. The tumor suppressor PTEN is exported in exosomes and has phosphatase activity in recipient cells. Sci Signaling 2012;5:ARTN ra70.
|
40 |
Putz U, Howitt J, Lackovic J et al. Nedd4 family-interacting protein 1 (Ndfip1) is required for the exosomal secretion of Nedd4 family proteins. J Biol Chem 2008;283:32621–32627.
|
41 |
Rak J, Guha A. Extracellular vesicles – vehicles that spread cancer genes. Bioessays 2012;34:489–497.
|
42 |
Salah Z, Alian A, Aqeilan RI. WW domain-containing proteins: retrospectives and the future. Front Biosci-Landmrk 2012;17:331–348.
|
43 |
Schuchardt BJ, Mikles DC, Hoang LM et al. Ligand binding to WW tandem domains of YAP2 transcriptional regulator is under negative cooperativity. FEBS J 2014;281:5532–5551.
|
44 |
Shao H, Im H, Castro CM et al. New technologies for analysis of extracellular vesicles. Chem Rev 2018;118:1917–1950.
|
45 |
Sterzenbach U, Putz U, Low LH et al. Engineered exosomes as vehicles for biologically active proteins. Mol Ther 2017;25:1269–1278.
|
46 |
Strzyz P. Iron expulsion by exosomes drives ferroptosis resistance. Nat Rev Mol Cell Biol 2020;21:4.
|
47 |
Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–249.
|
48 |
Teng Y, Ren Y, Hu X et al. MVP-mediated exosomal sorting of miR-193a promotes colon cancer progression. Nat Commun 2017;8:14448.
|
49 |
Tian Z, He W, Tang J et al. Identification of important modules and biomarkers in breast cancer based on WGCNA. Onco Targets Ther 2020;13:6805–6817.
|
50 |
Trajkovic K, Hsu C, Chiantia S et al. Ceramide triggers budding of exosome vesicles into multivesicular Endosomes. Science 2008;319:1244–1247.
|
51 |
Varelas X, Sakuma R, Samavarchi-Tehrani P et al. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol 2008;10:837–848.
|
52 |
Wagle MV, Marchingo JM, Howitt J et al. The ubiquitin ligase adaptor NDFIP1 selectively enforces a CD8(+) T cell tolerance check-point to high-dose antigen. Cell Rep 2018;24:577–584.
|
53 |
Xie H, Wu L, Deng Z et al. Emerging roles of YAP/TAZ in lung physiology and diseases. Life Sci 2018;214:176–183.
|
54 |
Yang S, Dong Q, Yao M et al. Establishment of an experimental human lung adenocarcinoma cell line SPC-A-1BM with high bone metastases potency by (99m)Tc-MDP bone scintigraphy. Nucl Med Biol 2009;36:313–321.
|
55 |
Yu Y, Song Z, Yang S et al. Everolimus and zoledronic acid—a potential synergistic treatment for lung adenocarcinoma bone metastasis. Acta Biochim Biophys Sin (Shanghai) 2014;46:792–801.
|
56 |
Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the roots of cancer. Cancer Cell 2016;29:783–803.
|
57 |
Zhang Y, Li D, Jiang Q et al. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. Cell Death Dis 2018;9:743.
|
58 |
Zhang L, Zhang S, Yao J et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature 2015;527:100–104.
|
59 |
Zhang YY, Zhang CB, Zhao Q et al. The miR-873/NDFIP1 axis promotes hepatocellular carcinoma growth and metastasis through the AKT/mTOR-mediated Warburg effect. Am J Cancer Res. 2019;9:927.
|
/
〈 | 〉 |